The traditional herbal medicine saireito exerts its inhibitory effect on murine oxazolone-induced colitis via the induction of Th1-polarized immune responses in the mucosal immune system of the colon

International Archives of Allergy and Immunology

Volumn 151, Issue 2, 2010, Pages 98-106

  Watanabe, Tetsuo ^a   Yamamoto, Takeshi ^a   Yoshida, Minako ^a   Fujiwara, Kanae ^a   Kageyama Yahara, Natsuko ^a   Kuramoto, Hirofumi ^b   Shimada, Yutaka ^a   Kadowaki, Makoto ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Oxazolone induced colitis; Saireito; SOCS 3; Th1 Th2 balance; Ulcerative colitis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; OXAZOLONE; SAIREI TO; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HERBAL MEDICINE; IMMUNE RESPONSE; IMMUNE SYSTEM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; TRADITIONAL MEDICINE; ULCERATIVE COLITIS; UPREGULATION;

ANIMALS; COLITIS, ULCERATIVE; COLON; DOWN-REGULATION; DRUGS, CHINESE HERBAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNITY, MUCOSAL; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-5; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXAZOLONE; SPLEEN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TH1 CELLS; TH2 CELLS; UP-REGULATION;

EID: 70049094066     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235999     Document Type: Article

References (43)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
2. Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640.
3. Hibi T, Ogata H: Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 2006; 41: 10-16.
4. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, Mc- Closkey EV, Mellstrom D: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899. (Pubitemid 41103445)
5. James ER: The etiology of steroid cataract. J Ocul Pharmacol Ther 2007; 23: 403-420.
6. Deshmukh CT: Minimizing side effects of systemic corticosteroids in children. Indian J Dermatol Venereol Leprol 2007; 73: 218-221.
7. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
8. Li FX, Verhoef MJ, Best A, Otley A, Hilsden RJ: Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol 2005; 19: 567-573.
9. Fujimoto M, Mori A, Sekiya N, Shimada Y, Terasawa K: Two cases of ulcerative colitis successfully treated with Kigi-kenchu-to (in Japanese). Jpn J Oriental Med 2004; 55: 655-660.
10. Ohno S: Roles of Kampo medicine in treating rheumatic diseases. J Trad Med 2007; 24: 73-80.
11. Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T: Effects of sairei-to on the relapse of steroid-dependent nephrotic syndrome. Am J Chin Med 1990; 18: 45-50.
12. Matsuike T, Yasumoto S, Nozawa H, Nishino H, Matsushima M, Kamakura H, Watanabe Y, Matsushima Y: Significance of treatment with Kampo medicines for ulcerative colitis. Prog Med 1999; 19: 879-885.
13. Okubo A, Masuda H, Hayashi S, Hayashi I, Yamagishi M, Aoki H, Taniguchi T, Kato K: Clinical study of Kampo-medicine (saireito) for ulcerative colitis. J Nihon Univ Med Assoc 1996; 55: 286-289.
14. Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521.
15. Boirivant M, Fuss IJ, Chu A, Strober W: Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188: 1929-1939.
16. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A: Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169: 195-207. (Pubitemid 29338733)
17. Wirtz S, Neufert C, Weigmann B, Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
18. Kawada M, Arihiro A, Mizoguchi E: Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 2007; 13: 5581-5593.
19. Iijima H, Neurath MF, Nagaishi T, Glickman JN, Nieuwenhuis EE, Nakajima A, Chen D, Fuss IJ, Utku N, Lewicki DN, Becker C, Gallagher TM, Holmes KV, Blumberg RS: Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med 2004; 199: 471-482.
20. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W: Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638.
21. Ishii M, Hashimoto S, Tsutsumi S, Wada Y, Matsushima K, Kodama T, Aburatani H: Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics 2000; 68: 136-143.
22. Cenac N, Cellars L, Steinhoff M, Andrade- Gordon P, Hollenberg MD, Wallace JL, Fiorucci S, Vergnolle N: Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis 2005; 11: 792-798.
23. Watanabe T, Yamamoto T, Yoshida M, Fujiwara K, Aburatani H, Shimada Y, Kadowaki M: Therapeutic effects of saireito, a traditional herbal medicine, in oxazolone induced mouse ulcerative colitis via the suppression of enhanced expression of the suppressor of cytokine signaling (SOCS)-3. Gastroenterology 2007; 132:A-394.
24. Fuse S, Shiotani Y, Shimada T, Terasawa K, Sagara K: Studies on the anti-inflammatory effects of the medicinal plant 'Saiko' ( Bupleurum falcatum L.). J Trad Med 1994; 11: 206-213.
25. Choi YA, Kang OH, Park HJ, Tae J, Kim DK, Kang CS, Choi SC, Yun KJ, Choi SJ, Nah YH, Kim YH, Bae KH, Lee YM: Effect of processed Scutellaria baicalensis on dextran sulfate sodium-induced colitis in mice. Int J Mol Med 2005; 16: 667-672.
26. Chung HL, Yue GG, To KF, Su YL, Huang Y, Ko WH: Effect of Scutellariae radix extract on experimental dextran-sulfate sodium-induced colitis in rats. World J Gastroenterol 2007; 13: 5605-5611.
27. Hofseth LJ, Wargovich MJ: Inflammation, cancer, and targets of ginseng. J Nutr 2007; 137: 183S-185S.
28. Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT: Anti-inflammatory effect of diammonium glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol 2006; 12: 4578-4581.
29. Ushio Y, Oda Y, Abe H: Effect of saikosaponin on the immune responses in mice. Int J Immunopharmacol 1991; 13: 501-508.
30. Hong T, Jin GB, Cho S, Cyong JC: Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med 2002; 68: 268-271.
31. Park EK, Choo MK, Han MJ, Kim DH: Ginsenoside Rh1 possesses antiallergic and antiinflammatory activities. Int Arch Allergy Immunol 2004; 133: 113-120.
32. Borchers AT, Hackman RM, Keen CL, Stern JS, Gershwin ME: Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr 1997; 66: 1303-1312.
33. Yamashiki M, Nishimura A, Watanabe J, Nakano T, Kosaka Y: Effects of the herbal medicine 'Sai-rei-to' on in vitro interferongamma production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992; 38: 153-160.
34. Fujii O, Kanai T, Kouzuma S, Baba K, Miki A, Hyodo H, Yamashita T, Unno N, Taketani Y: Herbal medicines, Sairei-to and Tokishakuyaku- san, differently modulate the release of cytokines from decidual versus peripheral blood mononuclear cells. Am J Reprod Immunol 2001; 46: 369-372. (Pubitemid 33034821)
35. Ito T, Seo N, Yagi H, Ohtani T, Tokura Y, Takigawa M, Furukawa F: Unique therapeutic effects of the Japanese-Chinese herbal medicine, Sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice. J Dermatol Sci 2002; 28: 198-210.
36. Asano T, Fujii Y, Numao N, Kageyama Y, Kihara K: The efficiency of Sairei-to for retroperitoneal fibrosis: two case reports. Hinyokika Kiyo 2006; 52: 543-547.
37. Alexander WS, Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22: 503-529.
38. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O: SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptorβ 2 subunit. Biochem Biophys Res Commun 2003; 310: 1188-1193.
39. Ekelund E, Saaf A, Tengvall-Linder M, Melen E, Link J, Barker J, Reynolds NJ, Meggitt SJ, Kere J, Wahlgren CF, Pershagen G, Wickman M, Nordenskjold M, Kockum I, Bradley M: Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006; 78: 1060-1065.
40. Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalano N, O'Garra A, Oshida T, Saito H, Johnston JA, Yoshimura A, Kubo M: SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003; 9: 1047-1054.
41. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-481.
42. Han X, Sosnowska D, Bonkowski EL, Denson LA: Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 2005; 129: 185-203.
43. Miyanaka Y, Ueno Y, Tanaka S, Yoshioka K, Hatakeyama T, Shimamoto M, Sumii M, Chayama K: Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis. World J Gastroenterol 2007; 13: 2939-2944.